Enanta Pharmaceuticals (ENTA) Payables (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Payables came in at $4.4 million in Q1 2026, down 8.26% YoY from $4.8 million in Q1 2025, and up 131.46% on a QoQ basis from $1.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Payables (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Payables data on file, last reported at $4.4 million in Q1 2026.
- Quarterly Payables fell 8.26% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 8.26% YoY) and the FY2025 annual result came in at $1.9 million, down 75.66% from the prior year.
- Payables climbed to $4.4 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $11.8 million in Q1 2023 to a low of $1.2 million in Q2 2022.
- A 5-year average of $5.7 million and a median of $4.8 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables slumped 78.88% — and 2023, when it jumped 537.11%.
- Tracing ENTA's Payables over 5 years: stood at $4.4 million in 2022, then soared by 114.29% to $9.3 million in 2023, then tumbled by 49.32% to $4.7 million in 2024, then sank by 60.11% to $1.9 million in 2025, then soared by 131.46% to $4.4 million in 2026.
- The last three Payables figures came in at $4.4 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 1.89 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Dec 31, 2024 | 4.73 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | 10.68 Mn |
| Mar 31, 2024 | 6.73 Mn |
| Dec 31, 2023 | 9.33 Mn |
| Sep 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 7.93 Mn |
| Mar 31, 2023 | 11.76 Mn |
| Dec 31, 2022 | 4.35 Mn |
| Sep 30, 2022 | 6.00 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 5.99 Mn |
| Dec 31, 2021 | 7.84 Mn |
| Sep 30, 2021 | 9.54 Mn |